U.S. Pharmaceutical CDMO Companies, Corporate Milestones, Corporate Growth and Development Strategy, Mergers and Acquisitions (M&A)

U.S. Pharmaceutical CDMO Companies and Competitive Landscape

The U.S. pharmaceutical CDMO market size is calculated at USD 36.77 billion in 2024, grew to USD 39.14 billion in 2025, and is projected to reach around USD 68.57 billion by 2034. The market is expanding at a CAGR of 6.43% between 2025 and 2034.

Top Companies in the U.S. Pharmaceutical CDMO

• Adare Pharma Solutions
• AGC Biologics
• Agilent Technologies
• Catalent Pharma Solutions
• Exela Pharma Sciences
• PCI Pharma Services
• Pfizer CentreOne
• Scorpius BioManufacturing
• Sharp Services
• Single Use Support
• Thermo Fisher Scientific
• UPM Pharmaceuticals, Inc.

Recent Developments in the U.S. Pharmaceutical CDMO Market

• In October 2024, Ardena announced a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. The acquisition was made to enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products. This will enable Ardena to become a leading global CDMO offering integrated solutions.
• In September 2024, PCI Pharma Services announced an investment of more than $365 million in complex, automated advanced drug delivery technologies to enhance capacities and capabilities at the company’s Biotech Center of Excellence in Philadelphia. The investment was made to strengthen the company’s position in innovations.

U.S. Consignee and Shipper Details in the U.S. Pharmaceutical CDMO Market